Revopsis Therapeutics, Inc.

Springfield, IL

UEI
GQ8PWEY4EMD9
CAGE
9DSH6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
4109 Chandlerwood Rd, Springfield, IL 62711, USA
Website
revopsis.com
Founded
2022
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Revopsis Therapeutics, Inc.'s latest federal award, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Transformational next generation high affinity trispecific FAB protein to address unmet needs in ophthalmology - project… Grant · R44EY035584 National Eye Institute $1,867,066

Quick answers

What is Revopsis Therapeutics, Inc.'s UEI?

Revopsis Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is GQ8PWEY4EMD9.

What is Revopsis Therapeutics, Inc.'s CAGE code?

Revopsis Therapeutics, Inc.'s CAGE code is 9DSH6.

What is Revopsis Therapeutics, Inc.'s primary NAICS code?

Revopsis Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Revopsis Therapeutics, Inc. located?

Revopsis Therapeutics, Inc.'s physical address in SAM.gov is 4109 Chandlerwood Rd, Springfield, IL 62711, USA.

Is Revopsis Therapeutics, Inc. registered in SAM.gov?

Yes. Revopsis Therapeutics, Inc.'s SAM.gov registration is active through August 6, 2027.

What is Revopsis Therapeutics, Inc.'s most recent federal award?

Revopsis Therapeutics, Inc.'s most recent federal grant award is Transformational next generation high affinity trispecific FAB protein to address unmet needs in ophthalmology - project… (R44EY035584), from National Eye Institute, on September 30, 2024.

On GovTribe

See Revopsis Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login